Synlait Cuts Bank Debt by NZ$200M After NZ$307M Asset Sale to Abbott
Synlait Milk Limited has completed the sale of its North Island assets to Abbott for NZ$307 million, significantly reducing its bank debt and refocusing its operations on Canterbury.
- NZ$307 million sale of North Island assets to Abbott completed
- Proceeds used to cut bank debt from NZ$400 million to NZ$200 million
- Sale includes Pōkeno manufacturing facility and Auckland leasehold sites
- Refinancing of remaining bank facilities underway
- Company acknowledges ongoing impact from FY25 manufacturing challenges
Strategic Asset Sale Marks a Turning Point
Synlait Milk Limited has taken a decisive step in reshaping its business by completing the NZ$307 million sale of its North Island assets to global healthcare giant Abbott. This transaction includes the Pōkeno manufacturing facility, associated inventory, and leasehold sites in Auckland, marking a significant divestment from the region.
CEO Richard Wyeth described the sale as a pivotal moment, enabling Synlait to simplify its operations and concentrate on its roots in Canterbury. The move reflects a strategic pivot towards strengthening the company’s core competencies and regional focus.
Debt Reduction and Financial Restructuring
The gross proceeds of approximately NZ$283.1 million have been largely earmarked for debt reduction. Synlait plans to use NZ$200 million to repay bank facilities, effectively halving its committed bank debt from NZ$400 million to NZ$200 million. This substantial deleveraging is a critical step in stabilising the company’s balance sheet after the financial strain caused by manufacturing challenges in the previous fiscal year.
Alongside the debt repayment, Synlait is actively pursuing refinancing of its remaining bank facilities, which now mature on 30 June 2026. The company’s overdraft facility remains unchanged at NZ$15 million, while various revolving credit and term loan limits have been reduced in line with the debt repayment.
Ongoing Challenges and Future Outlook
Despite the positive impact of the asset sale on Synlait’s financial position, the company acknowledges that the aftermath of FY25’s manufacturing issues continues to weigh on its balance sheet. The sale proceeds provide breathing room, but further work is needed to fully recover and return to growth.
Investors will be watching closely as Synlait navigates the refinancing process and implements its recovery strategy. The company’s ability to stabilise operations and capital structure will be key to regaining market confidence and delivering sustainable performance.
Bottom Line?
Synlait’s asset sale and debt cut set the stage for recovery, but refinancing and operational resilience remain critical.
Questions in the middle?
- How will Synlait manage refinancing risks given the June 2026 maturity dates?
- What impact will the loss of North Island assets have on Synlait’s production capacity?
- How effectively can Synlait address the lingering effects of FY25 manufacturing challenges?
